BioSpace News Archive

Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Michael MacLean as Chief Financial Officer.

Amplyx Pharmaceuticals, a biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that it has closed a $53 million Series C extension, which brings the Series C round to over $90 million.

Completes Enrollment of Phase 2 Candida Trial Treats First Patients in Phase 2 Trials in Aspergillus and Candida auris Infections

Duchesnay USA, a pharmaceutical company dedicated to women’s health, and PlushCare, a virtual health platform are announcing that women who are experiencing menopause symptoms can now request a virtual appointment with an independent healthcare provider via the PlushCare platform through osphena.com.

New study confirms hanging drop microfluidics platform for miniaturized islet perifusion assays enables high-resolution assessment of islet insulin secretion from single human islets over time.

Acquisition to expand global footprint, enhance product development and broaden Adaptas’ scientific instrument industry leadership position

BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company committed to developing first-in-class, curative immuno-oncology therapeutics, today announced that it has established operations at a new corporate headquarters and laboratory facilities at the Open Medicine Institute (OMI) Colla

Funding Will Accelerate the Development of ChromaCode Assays for Infectious Disease, Targeted Toward Resource-Limited Communities Worldwide

U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) filing to study the use of Alvesco in COVID-19 Study will evaluate the Safety and Efficacy of Alvesco in the Treatment of Non-hospitalized COVID-19 Patients Aged 12 and Above

Accuray Incorporated (NASDAQ: ARAY) today announced that MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market, has selected the Accuray Synchrony® Real-time Adaptive Technology